Vor Biopharma (NASDAQ:VOR) Shares Gap Down Following Insider Selling

Vor Biopharma Inc. (NASDAQ:VOR)’s stock price gapped down prior to trading on Tuesday after an insider sold shares in the company. The stock had previously closed at $16.27, but opened at $15.73. Vor Biopharma shares last traded at $14.43, with a volume of 627,880 shares.

Specifically, Director Ra Capital Management, L.P. sold 589,257 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $16.59, for a total value of $9,775,773.63. Following the completion of the sale, the director owned 4,555,741 shares of the company’s stock, valued at approximately $75,579,743.19. The trade was a 11.45% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ra Capital Management, L.P. sold 260,000 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $18.23, for a total value of $4,739,800.00. Following the completion of the sale, the director directly owned 5,144,998 shares of the company’s stock, valued at approximately $93,793,313.54. The trade was a 4.81% decrease in their position. The SEC filing for this sale provides additional information.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Jefferies Financial Group assumed coverage on Vor Biopharma in a research note on Monday, March 30th. They issued a “buy” rating and a $50.00 price target for the company. Wells Fargo & Company began coverage on Vor Biopharma in a research note on Thursday, March 19th. They issued an “overweight” rating and a $30.00 price target for the company. JPMorgan Chase & Co. reduced their target price on Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating for the company in a report on Friday, December 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, January 21st. Finally, Citigroup began coverage on Vor Biopharma in a report on Friday, January 9th. They issued a “buy” rating and a $50.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $50.67.

Vor Biopharma Price Performance

The company has a market capitalization of $823.09 million, a price-to-earnings ratio of -0.04 and a beta of 1.92. The business has a fifty day moving average price of $14.29 and a 200 day moving average price of $17.27.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. acquired a new position in shares of Vor Biopharma in the fourth quarter valued at $36,000. Goldman Sachs Group Inc. raised its stake in shares of Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after purchasing an additional 58,247 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Vor Biopharma in the second quarter valued at $66,000. Chung Wu Investment Group LLC acquired a new position in shares of Vor Biopharma in the fourth quarter valued at $109,000. Finally, Susquehanna Portfolio Strategies LLC acquired a new position in shares of Vor Biopharma in the fourth quarter valued at $134,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).